Incannex Submits IND for IHL-42X for Sleep Apnea

Incannex Healthcare Ltd, a clinical-stage pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies, has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for IHL-42X for the treatment of obstructive sleep apnea. The IND dossier compiled by the Incannex team includes comprehensive modules on the safety…

Read More